Logo image of HROW

HARROW INC (HROW) Stock Fundamental Analysis

NASDAQ:HROW - Nasdaq - US4158581094 - Common Stock - Currency: USD

31.75  +1.18 (+3.86%)

After market: 31.85 +0.1 (+0.31%)

Fundamental Rating

4

Overall HROW gets a fundamental rating of 4 out of 10. We evaluated HROW against 195 industry peers in the Pharmaceuticals industry. HROW has a medium profitability rating, but doesn't score so well on its financial health evaluation. HROW shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

5

1. Profitability

1.1 Basic Checks

In the past year HROW has reported negative net income.
In the past year HROW had a positive cash flow from operations.
HROW had negative earnings in each of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: HROW reported negative operating cash flow in multiple years.
HROW Yearly Net Income VS EBIT VS OCF VS FCFHROW Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M

1.2 Ratios

HROW has a better Return On Assets (-5.96%) than 72.82% of its industry peers.
HROW's Return On Equity of -38.43% is in line compared to the rest of the industry. HROW outperforms 56.41% of its industry peers.
HROW has a better Return On Invested Capital (2.13%) than 79.49% of its industry peers.
The Average Return On Invested Capital over the past 3 years for HROW is significantly below the industry average of 14.87%.
The last Return On Invested Capital (2.13%) for HROW is above the 3 year average (1.25%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA -5.96%
ROE -38.43%
ROIC 2.13%
ROA(3y)-7.09%
ROA(5y)-9.18%
ROE(3y)-36.88%
ROE(5y)-57.31%
ROIC(3y)1.25%
ROIC(5y)1.34%
HROW Yearly ROA, ROE, ROICHROW Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K

1.3 Margins

Looking at the Operating Margin, with a value of 2.24%, HROW is in the better half of the industry, outperforming 78.46% of the companies in the same industry.
In the last couple of years the Operating Margin of HROW has grown nicely.
HROW's Gross Margin of 74.53% is amongst the best of the industry. HROW outperforms 81.54% of its industry peers.
HROW's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 2.24%
PM (TTM) N/A
GM 74.53%
OM growth 3Y20.78%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.21%
GM growth 5Y2.29%
HROW Yearly Profit, Operating, Gross MarginsHROW Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

1

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), HROW is destroying value.
HROW has more shares outstanding than it did 1 year ago.
HROW has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, HROW has an improved debt to assets ratio.
HROW Yearly Shares OutstandingHROW Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
HROW Yearly Total Debt VS Total AssetsHROW Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

An Altman-Z score of 2.19 indicates that HROW is not a great score, but indicates only limited risk for bankruptcy at the moment.
HROW has a better Altman-Z score (2.19) than 68.21% of its industry peers.
HROW has a Debt/Equity ratio of 1.99. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of HROW (1.99) is worse than 76.92% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.99
Debt/FCF N/A
Altman-Z 2.19
ROIC/WACC0.21
WACC10.18%
HROW Yearly LT Debt VS Equity VS FCFHROW Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 0.91 indicates that HROW may have some problems paying its short term obligations.
The Current ratio of HROW (0.91) is worse than 85.13% of its industry peers.
A Quick Ratio of 0.85 indicates that HROW may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.85, HROW is doing worse than 81.03% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.91
Quick Ratio 0.85
HROW Yearly Current Assets VS Current LiabilitesHROW Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

7

3. Growth

3.1 Past

HROW shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 37.78%, which is quite impressive.
The Revenue has grown by 53.49% in the past year. This is a very strong growth!
Measured over the past years, HROW shows a very strong growth in Revenue. The Revenue has been growing by 31.29% on average per year.
EPS 1Y (TTM)37.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-31.58%
Revenue 1Y (TTM)53.49%
Revenue growth 3Y40.17%
Revenue growth 5Y31.29%
Sales Q2Q%38.29%

3.2 Future

HROW is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 118.14% yearly.
HROW is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 29.43% yearly.
EPS Next Y185.82%
EPS Next 2Y131.25%
EPS Next 3Y118.14%
EPS Next 5YN/A
Revenue Next Year45.77%
Revenue Next 2Y41.9%
Revenue Next 3Y40.21%
Revenue Next 5Y29.43%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
HROW Yearly Revenue VS EstimatesHROW Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
HROW Yearly EPS VS EstimatesHROW Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 1 -1 2 3

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

HROW reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
HROW is valuated rather expensively with a Price/Forward Earnings ratio of 21.56.
72.31% of the companies in the same industry are more expensive than HROW, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 21.90. HROW is around the same levels.
Industry RankSector Rank
PE N/A
Fwd PE 21.56
HROW Price Earnings VS Forward Price EarningsHROW Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 -40

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, HROW is valued a bit cheaper than the industry average as 76.92% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 62.72
HROW Per share dataHROW EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

HROW's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
HROW's earnings are expected to grow with 118.14% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y131.25%
EPS Next 3Y118.14%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for HROW!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HARROW INC

NASDAQ:HROW (7/3/2025, 7:34:20 PM)

After market: 31.85 +0.1 (+0.31%)

31.75

+1.18 (+3.86%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)08-05 2025-08-05/amc
Inst Owners57.24%
Inst Owner Change0.5%
Ins Owners15.07%
Ins Owner Change16.87%
Market Cap1.17B
Analysts83.64
Price Target56.98 (79.46%)
Short Float %13.04%
Short Ratio9.28
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-375.73%
Min EPS beat(2)-970.3%
Max EPS beat(2)218.83%
EPS beat(4)2
Avg EPS beat(4)-216.22%
Min EPS beat(4)-970.3%
Max EPS beat(4)218.83%
EPS beat(8)2
Avg EPS beat(8)-262.97%
EPS beat(12)3
Avg EPS beat(12)-1238.92%
EPS beat(16)4
Avg EPS beat(16)-1032.22%
Revenue beat(2)1
Avg Revenue beat(2)-5.85%
Min Revenue beat(2)-17.73%
Max Revenue beat(2)6.04%
Revenue beat(4)2
Avg Revenue beat(4)-1.84%
Min Revenue beat(4)-17.73%
Max Revenue beat(4)12.87%
Revenue beat(8)3
Avg Revenue beat(8)-3.1%
Revenue beat(12)5
Avg Revenue beat(12)-2.47%
Revenue beat(16)9
Avg Revenue beat(16)0.14%
PT rev (1m)-2.74%
PT rev (3m)-3.48%
EPS NQ rev (1m)-59.53%
EPS NQ rev (3m)-49.58%
EPS NY rev (1m)-24.45%
EPS NY rev (3m)-28.53%
Revenue NQ rev (1m)-2.42%
Revenue NQ rev (3m)-6.76%
Revenue NY rev (1m)0.38%
Revenue NY rev (3m)0.86%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 21.56
P/S 5.47
P/FCF N/A
P/OCF 556.46
P/B 20.64
P/tB N/A
EV/EBITDA 62.72
EPS(TTM)-0.56
EYN/A
EPS(NY)1.47
Fwd EY4.64%
FCF(TTM)-1
FCFYN/A
OCF(TTM)0.06
OCFY0.18%
SpS5.8
BVpS1.54
TBVpS-3.44
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -5.96%
ROE -38.43%
ROCE 2.69%
ROIC 2.13%
ROICexc 3.41%
ROICexgc N/A
OM 2.24%
PM (TTM) N/A
GM 74.53%
FCFM N/A
ROA(3y)-7.09%
ROA(5y)-9.18%
ROE(3y)-36.88%
ROE(5y)-57.31%
ROIC(3y)1.25%
ROIC(5y)1.34%
ROICexc(3y)2.44%
ROICexc(5y)3.09%
ROICexgc(3y)9.66%
ROICexgc(5y)8.29%
ROCE(3y)1.58%
ROCE(5y)1.69%
ROICexcg growth 3Y16.24%
ROICexcg growth 5YN/A
ROICexc growth 3Y-9.77%
ROICexc growth 5YN/A
OM growth 3Y20.78%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.21%
GM growth 5Y2.29%
F-Score7
Asset Turnover0.58
Health
Industry RankSector Rank
Debt/Equity 1.99
Debt/FCF N/A
Debt/EBITDA 5.35
Cap/Depr 237.77%
Cap/Sales 18.17%
Interest Coverage 0.22
Cash Conversion 9.95%
Profit Quality N/A
Current Ratio 0.91
Quick Ratio 0.85
Altman-Z 2.19
F-Score7
WACC10.18%
ROIC/WACC0.21
Cap/Depr(3y)528.86%
Cap/Depr(5y)344.75%
Cap/Sales(3y)46.48%
Cap/Sales(5y)28.73%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)37.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-31.58%
EPS Next Y185.82%
EPS Next 2Y131.25%
EPS Next 3Y118.14%
EPS Next 5YN/A
Revenue 1Y (TTM)53.49%
Revenue growth 3Y40.17%
Revenue growth 5Y31.29%
Sales Q2Q%38.29%
Revenue Next Year45.77%
Revenue Next 2Y41.9%
Revenue Next 3Y40.21%
Revenue Next 5Y29.43%
EBIT growth 1Y165.06%
EBIT growth 3Y69.3%
EBIT growth 5YN/A
EBIT Next Year1568.1%
EBIT Next 3Y280.43%
EBIT Next 5Y132.11%
FCF growth 1Y73.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y128.03%
OCF growth 3YN/A
OCF growth 5YN/A